Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Biotech Firm Durata Plans To Go Public

by Lisa M. Jarvis
April 2, 2012 | A version of this story appeared in Volume 90, Issue 14

Durata Therapeutics is hoping to raise $86 million through an initial public offering of stock, according to a recent Securities & Exchange Commission filing. Durata was formed in late 2009 to commercialize dalbavancin, an antibiotic licensed from Pfizer. Pfizer acquired the drug in 2005 through its $1.9 billion purchase of Vicuron. Dalbavancin, a long-acting lipoglycopeptide, is in two Phase III studies for treating acute bacterial skin and skin structure infections.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.